Antibodies, known for their precision in targeting diseases like cancer and autoimmune disorders, are challenging to model due to their flexible and diverse structures. To address this, A-Alpha Bio developed AlphaBind, an AI model designed to predict and optimize antibody-antigen binding affinity. Leveraging NVIDIA and AWS technology, AlphaBind uses experimental data and advanced machine learning… Continue reading In-Silico Antibody Development with AlphaBind Using NVIDIA BioNeMo and AWS HealthOmics